338 related articles for article (PubMed ID: 24596973)
21. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
[No Abstract] [Full Text] [Related]
22. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
Deleu D; Hanssens Y
Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16721952
[No Abstract] [Full Text] [Related]
23. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Gancher ST; Woodward WR; Nutt JG
Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
[TBL] [Abstract][Full Text] [Related]
24. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
25. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
Lieberman A; Le Brun Y; Boal D; Zolfaghari M
Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
[No Abstract] [Full Text] [Related]
26. [Limits of conventional oral and transdermal medication in Parkinson's disease].
García-Ruiz PJ; Luquin MR
Rev Neurol; 2012; 55 Suppl 1():S3-6. PubMed ID: 23169231
[TBL] [Abstract][Full Text] [Related]
27. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
Drapier S; Vérin M
Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing dopaminergic therapy of Parkinson's disease.
Horowski R
Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
[No Abstract] [Full Text] [Related]
29. [Diagnosis and therapy of Parkinson's disease].
Wittstock M; Benecke R
MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
[TBL] [Abstract][Full Text] [Related]
30. The effect of levodopa on the habituation of the acoustic-palpebral reflex in Parkinson's disease.
Rey RD; Garretto NS; Bueri JA; Simonetti DD; Sanz OP; Sica RE
Electromyogr Clin Neurophysiol; 1996 Sep; 36(6):357-60. PubMed ID: 8891475
[TBL] [Abstract][Full Text] [Related]
31. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
Destée A; Bordet R
Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
[TBL] [Abstract][Full Text] [Related]
32. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems.
Carlsson A
J Neural Transm (Vienna); 2002 May; 109(5-6):777-87. PubMed ID: 12111467
[No Abstract] [Full Text] [Related]
35. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's.
Djamshidian A; Poewe W
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S9-S12. PubMed ID: 28012951
[TBL] [Abstract][Full Text] [Related]
36. The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?
Dijk JM; Espay AJ; Katzenschlager R; de Bie RMA
J Parkinsons Dis; 2020; 10(s1):S65-S73. PubMed ID: 32651333
[TBL] [Abstract][Full Text] [Related]
37. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
Bachmann CG; Zapf A; Brunner E; Trenkwalder C
Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
[TBL] [Abstract][Full Text] [Related]
38. [Association between amytrophic lateral sclerosis and Parkinson's disease].
Alonso-Navarro H; Ruiz-Ezquerro JJ; Adeva-Bartolomé T; Jiménez-Jiménez FJ
Med Clin (Barc); 2007 Oct; 129(12):478-9. PubMed ID: 17953916
[No Abstract] [Full Text] [Related]
39. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Parkinson's disease. Advances in the pharmacological therapy.
Ghika J
Eur Neurol; 1996; 36(6):396-9. PubMed ID: 8954312
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
